BioNexus Gene Lab Corp. (BGLC)
| Market Cap | 2.43M -74.5% |
| Revenue (ttm) | 3.13M -67.3% |
| Net Income | -2.58M |
| EPS | -1.19 |
| Shares Out | 2.93M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,158 |
| Open | 0.8566 |
| Previous Close | 0.8565 |
| Day's Range | 0.8250 - 0.8566 |
| 52-Week Range | 0.8250 - 5.4100 |
| Beta | 1.96 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 20, 2026 |
About BGLC
BioNexus Gene Lab Corp., together with its subsidiaries, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company operates through three segments: Trading of Industrial Chemicals; Provision for Genomic Screening Services; and Investment Holding. It offers various chemical raw material products, including polyester resin SHCP 268, a thixotropic, quick-curing unsatura... [Read more]
Financial Performance
In 2025, BioNexus Gene Lab's revenue was $7.42 million, a decrease of -21.93% compared to the previous year's $9.51 million. Losses were -$2.98 million, 86.7% more than in 2024.
Financial StatementsNews
BioNexus Launches BGLC 1Lab Pilot for GeneMatrix Workflows at MRNA Scientific
KUALA LUMPUR, Malaysia, Nov. 03, 2026 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (Nasdaq: BGLC) ("BioNexus" or the "Company") today introduced BGLC 1Lab, its laboratory workflow product, and announce...
BioNexus Launches New Corporate Website with Expanded Business and Investor Resources
KUALA LUMPUR, Malaysia, Oct. 30, 2026 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (Nasdaq: BGLC) (“BioNexus” or the “Company”) today announced the launch of its redesigned corporate website at www.bio...
BioNexus to Build AI Applications for Malaysian Healthcare Under Exclusive CogniAI Licence
Licence of up to 20 years, payable in shares, as Malaysia commits RM1 billion to digitalizing public healthcare Licence of up to 20 years, payable in shares, as Malaysia commits RM1 billion to digital...
Ruanyun Edai Technology to enter Malaysia through Bionexus Gene Lab license pact
Ruanyun Edai Technology (RYET) announced that it has signed a definitive agreement under which, on closing, Ruanyun Edai Technology would grant BioNexus Gene Lab (BGLC) an exclusive license of its…
BioNexus Advances VitaGuard™ Southeast Asia Rollout Following China Working Visit
KUALA LUMPUR, Malaysia, July 28, 2026 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (Nasdaq: BGLC) ("BioNexus" or the "Company") today announced continued progress toward commercializing the VitaGuard™ ...
BioNexus Gene Lab Corp. Calls for Malaysia–China Biotechnology Cooperation to Move Beyond Trade into Co-Development
KUALA LUMPUR, Malaysia, May 29, 2026 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (Nasdaq: BGLC) (“BioNexus” or the “Company”), a technology-focused company advancing innovation across biotechnology, p...
Bionexus Gene Lab appoints Muthu Meyyappan as CCO, Fidelion
BioNexus Gene Lab (BGLC) announced that, in connection with its Fidelion Diagnostics transaction, Dr. Muthu Meyyappan has been appointed Chief Commercial Officer of Fidelion. Dr. Meyyappan will lead F...
BioNexus Gene Lab Corp. Announces Appointment of Dr. Muthu Meyyappan as Chief Commercial Officer of Fidelion Diagnostics to Lead Global Commercialization of the VitaGuard™ MRD Platform
KUALA LUMPUR, Malaysia, March 11, 2026 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ: BGLC) today announced that, in connection with its Fidelion Diagnostics Pte. Ltd (“Fidelion”) transaction, D...
Bionexus Gene Lab appoints Matthew Barsing as Chairman
BioNexus Gene Lab (BGLC) announced the completion of a governance restructuring of its wholly owned subsidiary, Chemrex Corporation. As part of this restructuring, Chemrex’s board has been streamlined...
BioNexus Gene Lab Corp. Completes Chemrex Governance Restructuring; Appoints Matthew Barsing as Chairman
Enhanced board oversight aligns subsidiary with disciplined capital allocation and strategic evaluation framework KUALA LUMPUR, Malaysia, Feb. 23, 2026 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (Nas...
Bionexus Gene Lab announces formal commencement of 2026 Deployment Phase
BioNexus Gene Lab (BGLC) announced the formal commencement of its 2026 Deployment Phase for the VitaGuard Minimal Residual Disease platform. This phase marks the transition of VitaGuard from a technol...
BioNexus Launches Regional Deployment of VitaGuard™ MRD Infrastructure; Positioned to Challenge Legacy Oncology Platforms Across ASEAN's Multi-Billion Dollar Market
KUALA LUMPUR, Malaysia, Jan. 28, 2026 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (Nasdaq: BGLC) (“BioNexus” or the “Company”), a technology-driven precision diagnostics company, today announced the f...
Bionexus Gene Lab completes investment in Fidelion Diagnostics
BioNexus Gene Lab (BGLC) announced the completion of its strategic transaction with Fidelion Diagnostics and Tongshu Biotechnology. With the closing of the agreements, BGLC has become a strategic shar...
BioNexus Gene Lab Corp. Completes Strategic Investment in Fidelion Diagnostics; Secures 15% Equity Stake in Global AI-Oncology Platform and Exclusive Southeast Asian Rights for VitaGuard™
KUALA LUMPUR, Malaysia, Dec. 03, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ: BGLC) ("BGLC" or the "Company"), a biotechnology company advancing precision diagnostics and gene-based techn...
Bionexus Gene Lab secures $500M equity facility from ARC Group
BioNexus Gene Lab (BGLC) entered into a $500,000,000 Equity Purchase Agreement with ARC Group International.The Company believes this facility will provide it with long-term, discretionary access to c...
BioNexus Gene Lab Corp. (Nasdaq: BGLC) Secures $500 Million Equity Facility From ARC Group International to Support Expansion of Precision Diagnostics, CDMO Operations, and Therapeutic Commercialization
SHERIDAN, Wyo., Dec. 02, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (“BGLC” or the “Company”), an emerging provider of precision oncology diagnostics with expanding operations across Southeast A...
Bionexus Gene Lab, Fidelion Diagnostics execute license for VitaGuard platform
BioNexus Gene Lab (BGLC) has executed an Exclusive Intellectual Property License Agreement for Southeast Asia with Fidelion Diagnostics for the VitaGuard minimal residual disease liquid biopsy platfor...
BioNexus Gene Lab Corp. (Nasdaq: BGLC) and Fidelion Diagnostics Execute Exclusive Southeast Asia License for VitaGuard™ MRD Platform as Part of Strategic Alliance with Tongshu Gene
KUALA LUMPUR, Malaysia and SINGAPORE, Dec. 01, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (“BGLC”) today announced that it has executed an Exclusive Intellectual Property License Agreement for S...
Bionexus enters agreements with Fidelion Diagnostics, Tongshu Biotechnology
BioNexus Gene Lab (BGLC) announced it has entered into definitive agreements with Fidelion Diagnostics and Tongshu Biotechnology, among other parties, to commercialize VitaGuard, a high-fidelity, tumo...
BioNexus Gene Lab Corp. (Nasdaq: BGLC) Announces Strategic Agreements with Fidelion Diagnostics for Southeast Asia MRD Commercialization
KUALA LUMPUR, Malaysia and SINGAPORE, Nov. 12, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (“BGLC,” Nasdaq: BGLC) today announced it has entered into definitive agreements with Fidelion Diagnosti...
Bionexus Gene Lab files $100M shelf registration, establishes $20M ATM program
BioNexus Gene Lab (BGLC) filed a registration statement on Form S-3 with the U.S. Securities and Exchange Commission to register up to $100 million of securities that may be offered…
BioNexus Gene Lab Corp. Files $100 Million Shelf Registration and Establishes $20 Million At-the-Market Program to Advance Strategic Growth Opportunities
KUALA LUMPUR, Malaysia, Nov. 10, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (Nasdaq: BGLC) (“BioNexus” or the “Company”), a biotechnology company advancing precision diagnostics and gene-based t...
Bionexus Gene Lab files $100M mixed securities shelf
16:33 EST Bionexus Gene Lab (BGLC) files $100M mixed securities shelf
Bionexus Gene Lab signs strategic partnership term sheet with BirchBioMed
BioNexus Gene Lab (BGLC) announced that it has entered into a non-binding Strategic Partnership Term Sheet with BirchBioMed, a Canadian biopharmaceutical company developing regenerative treatments for...
BioNexus Gene Lab Corp Signs Strategic Partnership Term Sheet with BirchBioMed Inc.
Collaboration Expected to Advance FS2 Topical Platform and Strengthen BGLC's Biotech Footprint in Asia Collaboration Expected to Advance FS2 Topical Platform and Strengthen BGLC's Biotech Footprint in...